Does Rallies track congressional trades in CRL?

Yes. Rallies tracks politician and congressional stock disclosures for CRL, including reported purchases, sales, dates, owners, and trade amounts when available.

Is CRL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CRL. It does not provide personalized investment advice.

CRL (Charles River Laboratories International, Inc.) Stock Analysis - Politician Trades

Charles River Laboratories International, Inc. (CRL) is a publicly traded Healthcare sector company. As of May 20, 2026, CRL trades at $156.24 with a market cap of $7.22B and a P/E ratio of -41.91. CRL moved +2.47% today. Year to date, CRL is -25.10%; over the trailing twelve months it is +8.71%. Its 52-week range spans $91.86 to $230.02. Analyst consensus is buy with an average price target of $205.38. Rallies surfaces CRL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded CRL stock?

Recent politician trading activity in CRL includes disclosures from Rob Bresnahan, Jefferson Shreve, Jefferson Shreve, Julie Johnson, and Ro Khanna. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.

CRL Key Metrics

Key financial metrics for CRL
Metric	Value
Price	$156.24
Market Cap	$7.22B
P/E Ratio	-41.91
EPS	$-3.70
Dividend Yield	0.00%
52-Week High	$230.02
52-Week Low	$91.86
Volume	747.46K
Avg Volume	0
Revenue (TTM)	$4.03B
Net Income	$-182.84M
Gross Margin	0.00%

Congressional Trades in CRL

Rob Bresnahan sale CRL on May 15, 2025 (amount: $15.00K).
Jefferson Shreve sale CRL on May 12, 2025 (amount: $50.00K).
Jefferson Shreve purchase CRL on May 8, 2025 (amount: $50.00K).
Julie Johnson purchase CRL on Jan 15, 2025 (amount: $15.00K) for Joint.
Ro Khanna purchase CRL on Nov 15, 2024 (amount: $15.00K).

Latest CRL News

Charles River shares rise after Q1 2026 results, guidance reaffirmed, divestiture completed — May 7, 2026
CRL jumps as CEO transition takes effect ahead of May 7 earnings catalyst — May 5, 2026
Charles River Labs jumps as bullish analyst catalyst hits ahead of May 7 earnings — May 4, 2026
Charles River (CRL) drops as divestiture-driven 2026 revenue cut and layoffs weigh — Apr 28, 2026
Charles River slips ahead of May earnings as divestiture-driven revenue reset hangs over 2026 outlook — Apr 23, 2026

Recent CRL Insider Trades

LaPlume Joseph W bought 25 (~$4.36K) on Mar 3, 2026.
LaPlume Joseph W sold 400 (~$65.49K) on Aug 22, 2025.
LaPlume Joseph W sold 800 (~$126.08K) on Aug 18, 2025.

CRL Analyst Consensus

10 analysts cover CRL: 0 strong buy, 7 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $205.38.

Common questions about CRL

Which politicians traded CRL stock?: Recent politician trading activity in CRL includes disclosures from Rob Bresnahan, Jefferson Shreve, Jefferson Shreve, Julie Johnson, and Ro Khanna. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in CRL?: Yes. Rallies tracks politician and congressional stock disclosures for CRL, including reported purchases, sales, dates, owners, and trade amounts when available.
Is CRL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CRL. It does not provide personalized investment advice.